DexCom v. Abbott Diabetes Care: Federal Circuit CGM Patent Appeal Dismissed in 24 Days
DexCom, Inc. and Abbott Diabetes Care Ltd. jointly agreed to dismiss a Federal Circuit infringement appeal covering two continuous glucose monitoring patents — US11000216B2 and US10959649B2 — in just 24 days. Each side bears its own costs, leaving the merits unresolved on the public record.
DexCom and Abbott exit Federal Circuit in 24 days — no merits ruling
DexCom, Inc. filed Case No. 25-1230 at the Court of Appeals for the Federal Circuit on 2 December 2024, asserting infringement claims relating to two patents: US11000216B2, covering medical device inserters and insertion processes for continuous glucose monitors, and US10959649B2, covering systems and methods for stride length calibration. Abbott Diabetes Care Ltd. was named as appellant or appellee in the proceeding, with both sides represented by prominent litigation firms — Keker, Van Nest & Peters for DexCom and Kirkland & Ellis alongside Latham & Watkins for Abbott.
The proceeding closed on 26 December 2024 — just 24 days after filing — when both parties jointly agreed to dismiss the appeal under Federal Rule of Appellate Procedure 42(b). The court ordered each side to bear its own costs. The public record is silent on whether the dismissal was with or without prejudice; the order references only the parties’ mutual agreement and the governing procedural rule, without specifying any merits-based resolution or settlement terms.
A 24-day lifespan for a Federal Circuit appeal is highly unusual and strongly suggests that a resolution — whether commercial settlement, licensing agreement, or strategic withdrawal — was reached almost immediately after the appeal was docketed. The mutual cost-bearing arrangement is consistent with a negotiated outcome rather than a unilateral concession. What drove the rapid resolution, and whether either patent remains enforceable or subject to further challenge, cannot be determined from the public record alone.
Filing to Voluntary dismissal in 24 days
24 days — resolved in under one month; exceptionally fast for a Federal Circuit appeal
Voluntarily dismissed: what the mutual exit means for both parties
Fed. R. App. P. 42(b): joint dismissal, no merits ruling
Federal Rule of Appellate Procedure 42(b) permits parties to dismiss an appeal by filing a signed agreement. The court issued no opinion on the underlying patent claims, claim construction, or validity. This means neither party secured a precedential ruling — the appeal simply ceases to exist procedurally. The substantive disputes over US11000216B2 and US10959649B2 remain unresolved as a matter of appellate law.
No merits adjudicationWith or without prejudice? The public record is silent
A voluntary dismissal may be with prejudice — barring re-filing — or without prejudice, leaving the door open to future litigation. The court’s order references only the parties’ agreement and Rule 42(b), without specifying either condition. This distinction has significant strategic consequences: if without prejudice, DexCom could potentially reassert these patents; if with prejudice, the appellate challenge is permanently closed. Practitioners should treat the position as uncertain absent further disclosure.
Prejudice status unclearAbbott exits without a liability finding — but uncertainty persists
Abbott Diabetes Care secured dismissal without any court finding of infringement or damages. However, the absence of a merits ruling also means Abbott did not obtain a declaration of non-infringement or invalidity that could shield it from future assertions of the same patents. The shared cost arrangement suggests neither party was in a clearly dominant litigation position at the time of dismissal, consistent with a negotiated exit.
No liability findingCGM sector: patent uncertainty over insertion and calibration tech remains
US11000216B2 and US10959649B2 cover commercially important CGM sub-technologies — device insertion mechanics and motion-based calibration. With no appellate ruling, competitors and new entrants in the wearable glucose monitoring space cannot rely on this proceeding to assess freedom to operate. The rapid resolution and mutual cost-bearing arrangement may signal that a broader commercial agreement between DexCom and Abbott is shaping the competitive landscape outside the courts.
FTO uncertainty remainsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | DexCom, Inc. | Company | Continuous glucose monitoring technology company — holder of US11000216B2 and US10959649B2Search in Eureka ↗ |
| Defendant | ABBOTT DIABETES CARE LTD. | Company | Abbott Diabetes Care Ltd. — subsidiary of Abbott Laboratories in the CGM device sectorSearch in Eureka ↗ |
| Plaintiff counsel | Eric B. Hanson | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Eugene M. Paige | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Matthew Mickle Werdegar | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Robert A. Van Nest | Attorney | Counsel for DexCom, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Keker, Van Nest & Peters LLP | Law Firm | Representing DexCom, Inc.Search in Eureka ↗ |
| Defendant counsel | Ashley N. Finger | Attorney | Counsel for ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant counsel | Gabriel K. Bell | Attorney | Counsel for ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant counsel | Jason M. Wilcox | Attorney | Counsel for ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant counsel | Michael A. Morin | Attorney | Counsel for ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant counsel | Paramjeet Singh Sammi | Attorney | Counsel for ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant counsel | Rachel Renee Blitzer | Attorney | Counsel for ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant counsel | Richard A. Lowry | Attorney | Counsel for ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant counsel | Srinivas Giriraj Pathmanaban Esq. | Attorney | Counsel for ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant law firm | Kirkland & Ellis LLP | Law Firm | Representing ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Defendant law firm | Latham & Watkins LLP | Law Firm | Representing ABBOTT DIABETES CARE LTD.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | Court of Appeals for the Federal CircuitSearch in Eureka ↗ |
Official order — verbatim text
The order’s phrasing — ‘The parties having so agreed’ — confirms this was a fully consensual exit with no judicial evaluation of the merits. The reference to Fed. R. App. P. 42(b) establishes the procedural vehicle. Notably, the order is silent on prejudice, leaving the future litigation posture of US11000216B2 and US10959649B2 ambiguous. The mutual cost-bearing provision is atypical where one party has a clearly superior position, suggesting approximate parity or a broader commercial resolution that made cost allocation immaterial.
US11000216B2 — CGM medical device inserters and insertion processes
US11000216B2 (Application No. US17/030030) covers medical device inserters and processes of inserting and using medical devices — a critical sub-technology in the continuous glucose monitoring ecosystem governing how sensors are placed subcutaneously. US10959649B2 (Application No. US14/608571) addresses systems and methods for stride length calibration, relevant to motion-compensation and accuracy in wearable biosensor contexts. Both patents sit at the intersection of hardware delivery mechanisms and sensor signal processing in the CGM space.
DexCom’s enforcement of these patents against Abbott — a direct CGM competitor with its own FreeStyle Libre platform — reflects the intensely contested IP environment in wearable glucose monitoring. Insertion mechanism patents and calibration method patents are strategically significant because they protect core user-experience differentiators. Any company developing next-generation CGM hardware or sensor fusion algorithms should treat both patents as active competitive risk vectors, particularly given the absence of any invalidity or non-infringement ruling from this proceeding.
Should your team run an FTO against US11000216B2 and US10959649B2?
Any company — startup or established medtech — developing CGM inserter mechanisms, subcutaneous sensor delivery systems, or wearable device calibration software should prioritise FTO analysis against both DexCom patents. The Federal Circuit appeal produced no claim construction ruling or invalidity finding, meaning the patents’ full scope remains defined solely by their claims and prosecution history. The DexCom–Abbott dispute demonstrates that these patents are actively enforced at the highest litigation level.
PatSnap Eureka’s FTO Search Agent can map your product’s technical features against the claim sets of US11000216B2 and US10959649B2, surface relevant prosecution history, identify continuation risk in DexCom’s broader CGM portfolio, and flag prior art that may support design-around strategies. Given the unresolved prejudice status of this dismissal, proactive monitoring of both patents for continuation filings or new assertions is strongly recommended for any CGM or wearable biosensor R&D team.
Run a freedom-to-operate analysis on US11000216B2 to assess your product’s exposure
Run FTO in Eureka →Similar CGM patent infringement appeals at the Federal Circuit
Explore Federal Circuit cases involving continuous glucose monitoring device patents, wearable medical sensor IP, and DexCom or Abbott patent enforcement actions.
What this case signals for the CGM and wearable medical device IP landscape
A 24-day Federal Circuit dismissal between two CGM rivals suggests commercial dynamics — not litigation attrition — are driving outcomes in this sector.
Speed of resolution signals a pre-existing or rapidly reached commercial deal
Federal Circuit appeals rarely resolve in under a month without an underlying commercial agreement. DexCom and Abbott’s 24-day exit is consistent with a licensing arrangement, cross-license expansion, or settlement reached before or immediately after docketing. IP teams monitoring CGM sector dynamics should watch for licensing disclosures in both companies’ financial filings.
No appellate ruling leaves both patents legally intact but strategically unresolved
Because the Federal Circuit issued no opinion, US11000216B2 and US10959649B2 carry no appellate history — positive or negative. Third parties cannot cite this case as precedent for or against the patents’ validity or scope. Any competitor operating in the CGM inserter or calibration space should conduct independent FTO analysis against both patents.
DexCom v ABBOTT — key questions answered
The Federal Circuit appeal (Case 25-1230) filed by DexCom, Inc. against Abbott Diabetes Care Ltd. was voluntarily dismissed after just 24 days, on 26 December 2024. Both parties jointly agreed to dismiss under Fed. R. App. P. 42(b), with each side bearing its own costs. No merits ruling was issued on the two patents involved: US11000216B2 and US10959649B2.
Two patents were asserted: US11000216B2, covering medical device inserters and processes of inserting and using medical devices (CGM sensor insertion technology), and US10959649B2, covering systems and methods for stride length calibration applicable to wearable medical devices. Both remain in force with no appellate validity or infringement ruling issued.
The public record does not specify. The court’s order references Fed. R. App. P. 42(b) and the parties’ mutual agreement but is silent on whether the dismissal is with or without prejudice. This distinction is legally significant — without prejudice would permit future reassertion; with prejudice would bar re-litigation of the same appellate claims. Practitioners should treat the position as unresolved absent further disclosure.
The 24-day resolution strongly suggests a pre-existing or rapidly negotiated commercial resolution — potentially a licensing agreement, cross-license amendment, or broader settlement — rather than a purely procedural decision. The mutual cost-bearing arrangement supports this reading, as it is inconsistent with one party having a clearly superior litigation position. The specific terms driving the exit are not disclosed in the public record.
Yes, significantly. Because the Federal Circuit issued no opinion on claim construction, validity, or infringement, neither US11000216B2 nor US10959649B2 has any adverse appellate history that third parties could rely on. Competitors in CGM insertion mechanisms or wearable calibration technology cannot use this case as FTO cover and should conduct independent patent clearance analysis against both patents.
PatSnap Eureka searches patents and litigation data to answer instantly.